Hou Ya Nan, Jin Yu Qin, Zhang Xue Feng, Tang Fang, Hou Jun Wei, Liu Zhao Ming, Han Zi Bo, Zhang Hao, Du Li Fang, Shao Shuai, Su Ji Guo, Liang Yu, Zhang Jing, Li Qi Ming
The Sixth Laboratory, National Vaccine and Serum Institute (NVSI) , Beijing, China.
National Engineering Center for New Vaccine Research , Beijing, China.
J Virol. 2023 Oct 31;97(10):e0093823. doi: 10.1128/jvi.00938-23. Epub 2023 Oct 4.
Human norovirus (HuNoV) is highly infectious and can result in severe illnesses in the elderly and children. So far, there is no effective antiviral drug to treat HuNoV infection, and thus, the development of HuNoV vaccines is urgent. However, NoV evolves rapidly, and currently, at least 10 genogroups with numerous genotypes have been found. The genetic diversity of NoV and the lack of cross-protection between different genotypes pose challenges to the development of broadly protective vaccines. In this study, guided by structural alignment between GI.1 and GII.4 HuNoV VP1 proteins, several chimeric-type virus-like particles (VLPs) were designed through surface-exposed loop grafting. Mouse immunization studies show that two of the designed chimeric VLPs induced cross-immunity against both GI.1 and GII.4 HuNoVs. To our knowledge, this is the first designed chimeric VLPs that can induce cross-immune activities across different genogroups of HuNoV, which provides valuable strategies for the development of cross-reactive HuNoV vaccines.
人诺如病毒(HuNoV)具有高度传染性,可导致老年人和儿童患重病。到目前为止,尚无有效的抗病毒药物治疗HuNoV感染,因此,开发HuNoV疫苗迫在眉睫。然而,诺如病毒进化迅速,目前已发现至少10个基因组群及众多基因型。诺如病毒的遗传多样性以及不同基因型之间缺乏交叉保护给广泛保护性疫苗的开发带来了挑战。在本研究中,以GI.1和GII.4 HuNoV VP1蛋白之间的结构比对为指导,通过表面暴露环嫁接设计了几种嵌合型病毒样颗粒(VLP)。小鼠免疫研究表明,所设计的两种嵌合VLP诱导了针对GI.1和GII.4 HuNoV的交叉免疫。据我们所知,这是首个能够诱导跨HuNoV不同基因组群产生交叉免疫活性的设计嵌合VLP,为开发交叉反应性HuNoV疫苗提供了有价值的策略。